SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin2000;60:277300.
  • 2
    Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol1983;15:1017.
  • 3
    Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol2004;11:11742.
  • 4
    Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al.Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer2006;94:6426.
  • 5
    Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, et al.Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol1999;74:38594.
  • 6
    Rosenberg P, Boeryd B, Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol Oncol1993;48:327.
  • 7
    Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol1982;6:93108.
  • 8
    Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med1981;105:61518.
  • 9
    Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, et al.Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol1994;54:2648.
  • 10
    Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol1992;16:60010.
  • 11
    Chambers JT, Merino M, Kohorn EI, Peschel RE, Schwartz PE. Uterine papillary serous carcinoma. Obstet Gynecol1987;69:10913.
  • 12
    O’Hanlan KA, Levine PA, Harbatkin D, Feiner C, Goldberg GL, Jones JG, et al.Virulence of papillary endometrial carcinoma. Gynecol Oncol1990;37:11219.
  • 13
    Sutton GP, Brill L, Michael H, Stehman FB, Ehrlich CE. Malignant papillary lesions of the endometrium. Gynecol Oncol1987;27:294304.
  • 14
    Thomas MB, Mariani A, Cliby WA, Keeney GA, Podratz KC, Dowdy SC. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol2007;107:1869.
  • 15
    Podratz KC, Mariani A. Uterine papillary serous carcinomas: the exigency for clinical trials. Gynecol Oncol2003;91:4612.
  • 16
    Chan JK, Loizzi V, Youssef M, Osann K, Rutgers J, Vasilev SA, et al.Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol2003;90:1815.
  • 17
    Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma?Gynecol Oncol1999;74:4657.
  • 18
    Grice J, Ek M, Greer B, Koh WJ, Muntz HG, Cain J, et al.Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol1998;69:6973.
  • 19
    Bristow RE, Asrari F, Trimble EL, Montz FJ. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I–III) disease. Gynecol Oncol2001;81:27986.
  • 20
    Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet2009;373:12536.
  • 21
    Gehrig PA, Groben PA, Fowler WC Jr, Walton LA, Van Le L. Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol2001;97:1537.
  • 22
    Kelly MG, O’Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, et al.Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol2004;95:46973.
  • 23
    Huh WK, Powell M, Leath CA 3rd, Straughn JM Jr, Cohn DE, Gold MA, et al.Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol2003;91:4705.
  • 24
    Kelly MG, O’Malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, et al.Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol2005;98:3539.
  • 25
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence – SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (1973–2006 varying) – Linked To County Attributes – Total US, 1969–2006, Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission. [http://www.seercancer.gov]. Last accessed 15 January 2011.
  • 26
    Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, Pomel C, Lhommé C, Duvillard P, Castaigne D, et al.Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg2003;197:198205.
  • 27
    Kumar S, Shah JP, Bryant CS, Imudia AN, Cote ML, Ali-Fehmi R, et al.The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol2008;110:12532.
  • 28
    Ries L, Fritz A. SEER Extent of Disease – 1988, 3rd edn. National Cancer Institute, 1998.
  • 29
    Collaborative Staging Task Force of the American Joint Committee on Cancer. Collaborative Staging Manual and Coding Instructions, version 010400. NIH Publication Number 04-5496 Incorporates updates through 8 September 2006, Chicago, IL and Bethesda, MD: American Joint Committee on Cancer and US Department of Health and Human Services, 2004.
  • 30
    Seiffert JE. SEER Program: Comparative Staging Guide for Cancer Version 11. National Cancer Institute, 1988.
  • 31
    Creasman WJ. Announcement, FIGO stages 1988, revisionsGynecol Oncol1989;31:1257.
  • 32
    Gitsch G, Friedlander ML, Wain GV, Hacker NF. Uterine papillary serous carcinoma. A clinical study. Cancer1995;75:223943.
  • 33
    Kato DT, Ferry JA, Goodman A, Sullinger J, Scully RE, Goff BA, et al.Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol1995;59:3849.
  • 34
    Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010 August 21.
  • 35
    Fader AN, Drake RD, O’Malley DM, Gibbons HE, Huh WK, Havrilesky LJ, et al.Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer2009;115:211927
  • 36
    Wright JD, Lewin SN, Barrena Medel NI, Sun X, Burke WM, Deutsch I, et al.Endometrial cancer in the oldest old: tumor characteristics, patterns of care, and outcome. Gynecol Oncol2011;Jul;122(1):6974.
  • 37
    Ahmed A, Zamba G, DeGeest K, Lynch CF. The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992–2002. Gynecol Oncol2008;111:3540.
  • 38
    Farley JH, Nycum LR, Birrer MJ, Park RC, Taylor RR. Age-specific survival of women with endometrioid adenocarcinoma of the uterus. Gynecol Oncol2000;79:869.
  • 39
    Hashiguchi Y, Hase K, Ueno H, Shinto E, Naito Y, Kajiwara Y, et al.Impact of race/ethnicity on prognosis in patients who underwent surgery for colon cancer: analysis for white, African, and East Asian Americans. Ann Surg Oncol2012;May;19(5):151728.
  • 40
    Krag DN, Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol2003;10:11529.
  • 41
    Weir L, Speers C, D’Yachkova Y, Olivotto IA. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol2002;20:17939.
  • 42
    Tepper JE, O’Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB 3rd, et al.Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol2001;19:15763.
  • 43
    Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst2007;99:43341.
  • 44
    Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol2003;21:102934.
  • 45
    Shah M, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ, et al.Therapeutic role of lymphadenectomy for cervical cancer. Cancer 2011 August 15;117:31017.
  • 46
    Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, et al.Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer2006;107:182330.